A Fourth Circuit oral argument this week highlighted a central post-Dobbs question: when the FDA has approved a drug and set conditions for its use, how much further can a state go? In the challenge to North Carolina’s restrictions on mifepristone, at least one judge appeared skeptical of the physician-plaintiff’s position, pressing the idea that federal drug regulation may establish a floor, not a ceiling.

That framing matters.